According to Nísia Trindade, studies show that the mutation identified in the United Kingdom does not compromise the effectiveness of the Oxford immunizer; researchers also analyze cases from South Africa and Brazil
The emergence of new variants of coronavirus should not impact the production schedule of immunizers against Covid-19 from Oswaldo Cruz Foundation (Fiocruz). The statement was made by the institution’s president, Nísia Trindade, in an interview with Jornal da Manhã, Young pan, this Tuesday, 23. According to her, initial studies indicate that the new strains do not jeopardize the effectiveness of Oxford vaccine, produced jointly with the pharmaceutical company AstraZeneca and currently distributed in the country. “The variants have no impact on our production or vaccine schedule. We already have evaluations regarding the effectiveness of the vaccine against the variants, the UK variant has already been proven to have had no impact on reducing efficiency of the vaccine, in the case of South Africa, it is important to verify, and there is a complete assessment of this, mainly the effectiveness in severe cases and hospitalizations. We are doing all the work of sequencing genomes in Brazil of the virus to have a picture of these variants in the country and to investigate the possible impact. ”
The concern about the possible consequences of the new mutations occurs at a time when the Brazilian strain, discovered in Manaus, advances through Brazilian states and, with a characteristic of greater transmissibility, drives the increase in cases and hospitalizations for Covid-19. Altogether, at least 200 cases of patients infected with the variant have already been reported in the country. According to Nísia Trindade, however, the appearance of other mutations may be driven by the low rate of immunization in the country. “The more the virus circulates, the more possibilities for variants to arise. This has to be the great national effort, of all countries. We all need to protect ourselves so that collective protection happens, ”he said. Contributing to accelerate vaccination in the country, Fiocruz receives on Tuesday another 2 million doses of the Oxford vaccine against Covid-19, produced at the Serum Institute, in India. The proposal is that the immunizers are distributed by the Ministry of Health Brazilian states.
The new shipment is part of a total of 12 million units of the compound that will be delivered in the coming months. In addition to the purchase of ready-made vaccines, the Oswaldo Cruz Foundation also awaits the arrival of the Active Pharmaceutical Ingredient (IFA) for the production of new immunizers. According to Nísia Trindade, the contract for technology transfer, which will allow the production of the vaccine with the national drug, should be signed in March. However, the delivery of immunizers with 100% of the compounds produced in the country should happen only in August. “It will be a process parallel to all production that we will do this year,” he said. Until then, the institution must deliver 100 million doses to the Brazilian government. “Our schedule foresees the delivery of 12 million vaccines in March and we will schedule in the coming months and make adjustments with receipt of the IFA. We will deliver 20 million in April, 20 million in May, and by July we will complete 100.4 million the Covid-19 Fiocruz vaccine. ”